Attached files
| file | filename |
|---|---|
| EX-10.51 - EX-10.51 - Theravance Biopharma, Inc. | tbph-20201231xex10d51.htm |
| 10-K - 10-K - Theravance Biopharma, Inc. | tbph-20201231x10k.htm |
| EX-10.60 - EX-10.60 - Theravance Biopharma, Inc. | tbph-20201231xex10d60.htm |
| EX-23.1 - EX-23.1 - Theravance Biopharma, Inc. | tbph-20201231xex23d1.htm |
| EX-31.1 - EX-31.1 - Theravance Biopharma, Inc. | tbph-20201231xex31d1.htm |
| EX-31.2 - EX-31.2 - Theravance Biopharma, Inc. | tbph-20201231xex31d2.htm |
| EX-32 - EX-32 - Theravance Biopharma, Inc. | tbph-20201231xex32.htm |
Exhibit 21.1
Subsidiaries
Theravance Biopharma US, Inc. (Delaware)
Theravance Biopharma UK Limited (England and Wales)
Theravance Biopharma Ireland Limited (Ireland)
Theravance Biopharma R&D IP, LLC (Delaware)
Theravance Biopharma Antibiotics IP, LLC (Delaware)
Theravance Biopharma US Holdings, Inc. (Delaware)
Triple Royalty Sub LLC (Delaware)
Triple Royalty Sub II LLC (Delaware)